Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
AbbVie
Biotech
AbbVie acquires oral peptide biotech Nimble for $200M
AbbVie is paying $200 million to acquire Nimble Therapeutics and its lead asset, a preclinical oral peptide being evaluated as a psoriasis treatment.
Gabrielle Masson
Dec 13, 2024 10:38am
AbbVie's Parkinson's prospect improves motor function in ph. 3
Dec 9, 2024 9:34am
Alector lays off 17% of staff after ph. 2 Alzheimer's drug fail
Nov 26, 2024 4:50am
AbbVie's $9B schizophrenia prospect flunks phase 2 trials
Nov 11, 2024 10:06am
AbbVie pays $65M for options on EvolveImmune's T-cell engagers
Oct 31, 2024 10:00am
AbbVie inks $1.4B Aliada buyout to land ex-J&J Alzheimer's drug
Oct 28, 2024 10:00am
